Ishares Nasdaq Biotechnology ETF (IBB)
$138.54 1.17 (0.85%)
19:38 EDT IBB Stock Quote Delayed 30 Minutes
Previous Close $138.54
Market Cap 12.05B
PE Ratio -
Volume (Avg. Vol.) 2.79M
Day's Range 137.68 - 139.82
52-Week Range 92.15 - 140.57
Dividend & Yield 0.31 (0.23%)
IBB Stock Predictions, Articles, and Ishares Nasdaq Biotechnology ETF News
- From InvestorPlace
- From the Web
Consensus is that the experts will find a vaccine to Covid-19 soon, so the biotech stocks have rallied hard. Buying them now carries risk.
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
The buyers are in charge of the healthcare stocks this year. And judging from their charts, these stocks and ETFs in particular offer great opportunities.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, is up 16.65% since Oct. 1, pushing its year-to-date gain to 26.57% as of Dec. 20. That after months of investors pulling money from actively managed biotech funds, but that situation is starting to correct as well as data out this month indicate investors are warming to biotech assets again.
Our research and analysis have identified another name in biotech stocks with big potential in 2020.
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
Amid ongoing industry consolidation, attractive valuations and a strong broad market, catalysts are in place for more upside for biotech ETFs.
The charts for the IBB ETF in multiple time frames suggest the recent rally in biotech stocks is overdone for the time being.